Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma

Video

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a frontline therapy for metastatic renal cell carcinoma (mRCC).

The randomized dose titration study enrolled approximately 200 patients with mRCC. Patients were first treated with the standard dose at 5 mg twice daily for 30 days. Criteria to be randomized to receive an increased dosage included a lack of incidence of toxicity and/or hypertension.

Patients were then randomized to an increased dose of axitinib versus placebo, which was the standard dose. A 20% advantage in response rate was demonstrated in the titration arm. Progression-free survival and overall survival was favored in the titration arm, but was not found to be statistically significant. Researchers determined that dose titration needs to be carefully done so as to not harm patients with higher levels of toxicities.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
© 2025 MJH Life Sciences

All rights reserved.